BrightPath Biotherapeutics CoTSE:4594 +2.04%46 Median PS Value is 円0.66 as of Jul. 11, 2026, which is 100% below its 10-year median of 104.55. GuruFocus rates TSE:4594 with a GF Score™ of 46/100 and a GF Value™ of 円4.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 278 Biotechnology companies, BrightPath Biotherapeutics Co ranks worse than 100% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for BrightPath Biotherapeutics Co's Median PS Value or its related term are showing as below:
TSE:4594'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 72.73 Med: 104.55 Max: 104.55
Current: 75.76
During the past 12 years, the highest Price to Median PS Value of BrightPath Biotherapeutics Co was 104.55. The lowest was 72.73. And the median was 104.55.
TSE:4594's Price-to-Median-PS-Value is ranked worse than 100% of 278
companies
in the Biotechnology industry
Industry Median: 0.645
vs TSE:4594: 75.76
BrightPath Biotherapeutics Co (TSE:4594) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BrightPath Biotherapeutics Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
50.00
/
0.66
=
75.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co Median PS Value Related Terms
BrightPath Biotherapeutics Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co Median PS Value Chart
TSE:4594 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BrightPath Biotherapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Median PS Value of 円0.66 as of Jul. 11, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BrightPath Biotherapeutics Co and its competitors. This is 99% below median its historical median of 104.55. Over the past decade, BrightPath Biotherapeutics Co's Median PS Value has ranged from 72.73 to 104.55. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #278 out of 278 companies in the Biotechnology industry.
Is BrightPath Biotherapeutics Co's Median PS Value too high?
BrightPath Biotherapeutics Co's current Median PS Value of 円0.66 is 99% below median its 10-year median of 104.55. Over the past 10 years, this metric has ranged from a low of 72.73 to a high of 104.55. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #278 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #278 out of 278 companies for Median PS Value. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median Median PS Value is 0.65. Historically, BrightPath Biotherapeutics Co's own Median PS Value has ranged from 72.73 to 104.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current Median PS Value is 円0.66, which is 99% below median its own 10-year median of 104.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.64, compared to a current price of 円50.00 — trading 977.6% above its estimated fair value. The current Median PS Value is 円0.66, which is 99% below median its 10-year median of 104.55. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Median PS Value is 円0.66 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
Median PS Value: 円0.66 (99% below median its 10-year median of 104.55)
GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Business Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score
Get the complete analysis for TSE:4594
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
